Table 1.
Patient characteristics
| Variables | Number of patients (n = 123) |
|---|---|
| Median age, years (range) | 64 (38–84) |
| Gender, n (%) | |
| Male | 65 (53) |
| Female | 58 (47) |
| ECOG-PS, n (%) | |
| 0 | 94 (76) |
| 1 | 27 (22) |
| 2 | 2 (2) |
| Tumor location, n (%) | |
| Head | 59 (48) |
| Body-Tail | 64 (52) |
| Median CEA, ng/mL (range) | 3.3 (0.7–70.1) |
| Median CA19-9, U/mL (range) | 366.8 (0.1–27,600) |
| Adjuvant therapy, n (%) | |
| Yes | 106 (87) |
| No | 3 (2) |
| Unknown | 14 (11) |
| Pathological diagnosis, n (%) | |
| Yes | 75 (61) |
| No | 48 (39) |
| Median tumor diameter, mm (range) | 32 (11–68) |
| Lymph node metastasis, n (%) | |
| Positive | 41 (33) |
| Negative | 82 (67) |
| Bile duct invasion, n (%) | |
| Positive | 63 (51) |
| Negative | 60 (49) |
| Duodenal invasion, n (%) | |
| Positive | 64 (52) |
| Negative | 59 (48) |
| Anterior peripancreatic invasion, n (%) | |
| Positive | 104 (85) |
| Negative | 19 (15) |
| Posterior peripancreatic invasion, n (%) | |
| Positive | 123 (100) |
| Negative | 0 (0) |
| Venous invasion, n (%) | |
| Positive | 123 (100) |
| Negative | 0 (0) |
| Arterial invasion, n (%) | |
| Positive | 123 (100) |
| Negative | 0 (0) |
| Extrapancreatic nerve plexus invasion, n (%) | |
| Positive | 123 (100) |
| Negative | 0 (0) |
| Median GTV volume, cc (range) | 44.0 (7.9–141.0) |
| Median CTV volume, cc (range) | 186.5 (85.0–420.6) |
| Median GTV V60GyE, % (range) | 59.4 (6.2–99.7) |
| Median CTV V60GyE, % (range) | 59.3(25.6–86.7) |
ECOG-PS Eastern Cooperative Oncology Group-Performance Status; CEA carcinoembryonic antigen; CA19-9 carbohydrate antigen 19–9; GTV gross tumor volume; CTV clinical target volume; GyE Gy equivalents; V60GyE the volume ratio irradiated over 60 GyE